Shares of Telomir Pharmaceuticals Inc. (NASDAQ:TELO) soared 150% on Thursday after the biotech firm unveiled compelling preclinical results for its experimental cancer therapy, Telomir-1. The data suggest the company’s lead drug candidate may significantly outperform standard cancer treatments in reactivating silenced tumor suppressor genes.
In recent laboratory studies, Telomir-1 was shown to restore the function of STAT1, a key regulator of immune surveillance, more effectively than widely used agents Paclitaxel and Rapamycin. In an aggressive human prostate cancer model, the compound fully reversed hypermethylation of STAT1 in a dose-dependent fashion over a 21-day oral regimen in mice.
Telomir believes this epigenetic reprogramming could reignite the body’s natural cancer-fighting mechanisms by enabling immune cells to recognize and eliminate tumor cells—a potential explanation for tumor regression observed in earlier studies.
“This study provides novel and direct molecular evidence of Telomir-1’s ability to reprogram cancer epigenetics,” said Erez Aminov, CEO of Telomir. “By potentially restoring the function of key tumor suppressor genes like STAT1, we’re not just slowing tumor growth—we’re turning the immune system back on.”
The company also reported that Telomir-1 reduced hypermethylation of TMS1, another gene involved in programmed cell death and inflammasome activation. The ability to simultaneously target both STAT1 and TMS1 sets Telomir-1 apart from conventional therapies evaluated in the study.
Telomir Pharmaceuticals focuses on drug development aimed at countering biological aging and treating age-associated illnesses. The company remains in the preclinical phase, with no therapies yet approved for commercial distribution.
Telomir Pharmaceuticals stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.